期刊简介
本杂志是由中华人民共和国卫生部主管，同济医科大学附属协和医院主办，国内外公开发行的学术性期刊，被国家科技部列为“中国科技论文统计源期刊”，被中国科学文献计量评价研究中心认定为《中国科学引文数据库》来源期刊。设有专家笔谈、临床研究、实验研究、研究报告、综述、进修苑、学术争鸣、经验介绍及病例报告等栏目。
往期目录
-
1999
-
2000
-
2001
-
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
首页>临床血液学杂志
- 杂志名称：临床血液学杂志
- 主管单位：中华人民共和国教育部
- 主办单位：华中科技大学同济医学院附属协和医院 北京大学医学院血研所
- 国际刊号：1004-2806
- 国内刊号：42-1284/R
- 出版周期：双月刊
期刊荣誉：中国核心期刊数据库收录期刊期刊收录：国家图书馆馆藏, 万方收录(中), 上海图书馆馆藏, CA 化学文摘(美), 统计源核心期刊(中国科技论文核心期刊), 知网收录(中), 维普收录(中)
骨髓士曾生异常综合征的造血干细胞移植治疗现状和进展
刘蕊；许兰平
关键词：骨髓增生异常综合征, 造血干细胞移植, 去甲基化药物
摘要：Currently,the only potential curative therapy for myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell transplantation (allo-HSCT),whose status is not moved in spite of the widespread using of hypomethylating agents (HMAs).Several prognostic scoring systems can be used for selecting candidates for alloHSCT.No conclusive evidence establishes that HMAs used as bridge treatment for modifying tumor burden prior to transplant can improve prognosis,thus an intended transplantation shouldn't be delayed for waiting for the effects of HMAs.Several retrospective studies have demonstrated the benefit of HMAs in prevention or treatment of relapse after allo-HSCT,though further evidence is needed.As haploidentical HSCT has a similar efficacy with matched HSCT in MDS treatment,the problem of lack of donor is settled in a degree.So this therapeutic method would attract more study interest and be applied more broadly.
友情链接